Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02455557 · ClinicalTrials.gov registry record · Phase 2

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

A Phase 2 study of Glioblastoma and Gliosarcoma, sponsored by Roswell Park Cancer Institute.

Active
Registry status
Phase 2
Development phase
66
Enrollment target
5
Study locations

NCT02455557 is a Phase 2 study of Glioblastoma and Gliosarcoma that is active but no longer recruiting, run by Roswell Park Cancer Institute. The registered enrollment target is 66 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (39% lower). The trial reports 5 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02455557, a Phase 2 study of Glioblastoma and Gliosarcoma, is active but no longer recruiting, sponsored by Roswell Park Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
66 participants
Enrollment target
5
Study locations

Study Summary

This phase II trial studies the side effects and how well vaccine therapy works when given together with temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from the survivin peptide or antigen may help the body build an effective immune response to kill tumor cells that express survivin. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether temozolomide is more effective with or without vaccine therapy in treating glioblastoma.

Conditions Studied

Glioblastoma Gliosarcoma

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Temozolomide
  • BIOLOGICAL Sargramostim
  • BIOLOGICAL SVN53-67/M57-KLH Peptide Vaccine
  • DRUG Montanide ISA 51 VG

Study Locations (5)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston
  • Dana-Farber Harvard Cancer Center - Boston
  • Beth Israel Deaconess Medical Center - Boston

New York

  • Roswell Park Cancer Institute - Buffalo

Ohio

  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2015-05-04
Est. Completion 2026-03-02
Phase Phase 2

Sponsor

Roswell Park Cancer Institute

365 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02455557

The ClinicalTrials.gov registry entry for NCT02455557 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (39% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02455557 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT02455557 about?

NCT02455557 is a clinical study titled "SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma". This phase II trial studies the side effects and how well vaccine therapy works when given together with temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from the survivin peptide or antigen may help the body build an effective immune response to kill tumor cells th...

What is the current status of trial NCT02455557?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2015-05-04. Estimated completion is 2026-03-02.

What conditions does trial NCT02455557 study?

This clinical trial studies the following conditions: Glioblastoma, Gliosarcoma.

What interventions are being tested in trial NCT02455557?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Temozolomide (DRUG), Sargramostim (BIOLOGICAL), SVN53-67/M57-KLH Peptide Vaccine (BIOLOGICAL), Montanide ISA 51 VG (DRUG).

Who is sponsoring clinical trial NCT02455557?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02455557 being conducted?

This trial has 5 study locations across Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma

All registered trials for this condition

Gliosarcoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.